Company profile: Soin Therapeutics
1.1 - Company Overview
Company description
- Provider of pharmaceutical drug development focused on new medications for rare, orphan diseases, including a novel formulation of low-dose naltrexone to treat CRPS.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Soin Therapeutics
Minoryx Therapeutics
HQ: Spain
Website
- Description: Provider of pharmacological chaperone small-molecule drugs for genetic, neurometabolic, and rare pediatric diseases. Develops leriglitazone, a selective PPAR gamma agonist for X-linked adrenoleukodystrophy and other CNS diseases, supported by phase 2/3 results. Programs include ADVANCE (adult X-ALD), NEXUS (pediatric cALD), CALYX (adult progressive cALD), and a Friedreich's ataxia proof-of-concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minoryx Therapeutics company profile →
Spexis
HQ: Switzerland
Website
- Description: Provider of macrocycle drug discovery and development addressing high unmet medical needs, offering ColiFin (EU-approved inhaled therapy for chronic infections in cystic fibrosis, seeking U.S. approval); inhaled murepavadin for Pseudomonas aeruginosa infections; balixafortide, a macrocyclic CXCR4 inhibitor; and Macrocycle and OMPTA platforms for rare diseases and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spexis company profile →
Satellos Bioscience
HQ: Canada
Website
- Description: Provider of regenerative medicine therapeutics to stimulate or restore muscle regeneration, leveraging the MyoReGenX proprietary discovery platform to identify muscle diseases and generate novel drug candidates; developing small molecule therapeutics for Duchenne muscular dystrophy via a dystrophin-independent pathway and advancing a series of AAK1 inhibitors to clinical trials to restore muscle repair and regeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satellos Bioscience company profile →
Imegen
HQ: Spain
Website
- Description: Provider of biomedical services and products for genetic analysis, offering diagnostic, prognostic, and preventive genetic services to improve health and quality of life, with the aim of being a worldwide reference in human genetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imegen company profile →
Artelo Biosciences
HQ: United States
Website
- Description: Provider of endocannabinoid system modulating therapeutics, including ART27.13, a synthetic dual CB1/CB2 GPCR agonist intended to increase appetite and reduce muscle wasting; ART26.12, a selective fatty acid binding protein inhibitor with potential in cancer and chemotherapy-induced peripheral neuropathy; and ART12.11, a proprietary cannabidiol–tetramethylpyrazine cocrystal designed to improve CBD's pharmaceutical properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artelo Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Soin Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Soin Therapeutics
2.2 - Growth funds investing in similar companies to Soin Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Soin Therapeutics
4.2 - Public trading comparable groups for Soin Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →